Compare RGLD & BAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGLD | BAX |
|---|---|---|
| Founded | 1981 | 1931 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8B | 13.9B |
| IPO Year | 1995 | 1994 |
| Metric | RGLD | BAX |
|---|---|---|
| Price | $252.31 | $26.41 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 9 |
| Target Price | ★ $262.17 | $21.00 |
| AVG Volume (30 Days) | 719.0K | ★ 7.7M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.82% | 0.24% |
| EPS Growth | ★ 32.74 | N/A |
| EPS | ★ 6.07 | 0.21 |
| Revenue | $1,030,471,000.00 | ★ $11,244,000,000.00 |
| Revenue This Year | $89.85 | $1.96 |
| Revenue Next Year | $5.05 | $2.22 |
| P/E Ratio | ★ $40.88 | $126.86 |
| Revenue Growth | ★ 43.24 | 5.72 |
| 52 Week Low | $168.88 | $15.73 |
| 52 Week High | $306.25 | $30.00 |
| Indicator | RGLD | BAX |
|---|---|---|
| Relative Strength Index (RSI) | 72.99 | 56.47 |
| Support Level | $214.71 | $18.74 |
| Resistance Level | $276.99 | $30.00 |
| Average True Range (ATR) | 5.79 | 0.89 |
| MACD | 3.26 | -0.28 |
| Stochastic Oscillator | 96.43 | 22.29 |
Royal Gold Inc enquires and manages precious metal royalties and streams with a focus on gold. The company purchases a percentage of the metal produced from a mineral property for an initial payment without assuming responsibility for mining operations. Similarly, precious metal streams are purchase agreements with mine operators providing the right to purchase all or a portion of one or more metals produced from a mine in exchange for an upfront deposit payment. Generally, Royal Gold does not work on the properties in which it holds royalty and streaming assets. The company owns a portfolio of producing, development, evaluation, and exploration royalties and streams, and the majority of group revenue is generated from Canada, Mexico, Chile, and the United States.
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.